NO20051779L - Immunisering mot autologt ghrelin - Google Patents
Immunisering mot autologt ghrelinInfo
- Publication number
- NO20051779L NO20051779L NO20051779A NO20051779A NO20051779L NO 20051779 L NO20051779 L NO 20051779L NO 20051779 A NO20051779 A NO 20051779A NO 20051779 A NO20051779 A NO 20051779A NO 20051779 L NO20051779 L NO 20051779L
- Authority
- NO
- Norway
- Prior art keywords
- ghrelin
- methods
- autologous
- autologous ghrelin
- immunization
- Prior art date
Links
- 101800001586 Ghrelin Proteins 0.000 title abstract 6
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 4
- 230000003053 immunization Effects 0.000 title abstract 3
- 238000002649 immunization Methods 0.000 title abstract 3
- 102000012004 Ghrelin Human genes 0.000 title 1
- 102400000442 Ghrelin-28 Human genes 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- -1 Ghrelin nucleic acid Chemical class 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SAMMENDRAG Oppfinnelsen beskriver nye fremgangsmåter som generelt angår immunisering mot autologt ghrelin. Immunisering blir fortrinnsvis utført ved å administrere analoger av autologt ghrelin og hvor nevnte analoger er i stand til å indusere antistoffproduksjon mot de autologe ghrelinpolypeptidene. Spesielt foretrukket som et irnmunogen er autologt ghrelin som er blitt modifisert ved innføring av en enkelt, eller noen få fremmede immunodominante og promiskuøse T-celleepitoper. Det er også beskrevet nukleinsyrevaksinasjon mot ghrelin, og vaksinasjon som anvender levende vaksiner, så vel som fremgangsmåter og anordninger som kan brukes for vaksinasjon. Slike fremgangsmåter og anordninger innbefatter fremgangsmåter for fremstilling av analoger og farmasøytiske sammensetninger så vel som nukleinsyrefragmenter, vektorer, transformerte celler, polypeptider og farmasøytiske preparater og sammensetninger.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41016402P | 2002-09-12 | 2002-09-12 | |
| DKPA200201345 | 2002-09-12 | ||
| PCT/DK2003/000592 WO2004024183A1 (en) | 2002-09-12 | 2003-09-12 | Immunization against autologous ghrelin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051779L true NO20051779L (no) | 2005-04-11 |
| NO20051779D0 NO20051779D0 (no) | 2005-04-11 |
Family
ID=31995413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051779A NO20051779D0 (no) | 2002-09-12 | 2005-04-11 | Immunisering mot autologt ghrelin |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1539232A1 (no) |
| JP (1) | JP2006504413A (no) |
| AU (1) | AU2003263150A1 (no) |
| CA (1) | CA2498739A1 (no) |
| MX (1) | MXPA05002699A (no) |
| NO (1) | NO20051779D0 (no) |
| WO (1) | WO2004024183A1 (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| WO2005097830A2 (en) * | 2004-04-07 | 2005-10-20 | Aditech Pharma Ab | Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds |
| WO2005097831A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of isolated binding members capable of binding specifically to secretagogues |
| GB0411014D0 (en) * | 2004-05-18 | 2004-06-23 | Haptogen Ltd | Methods for the control treatment and management of obesity |
| EP1856154A1 (en) * | 2005-02-23 | 2007-11-21 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
| US8992928B2 (en) | 2006-02-11 | 2015-03-31 | Victor Raso | Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin |
| US20110105389A1 (en) | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20010020012A1 (en) * | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| WO2001087335A2 (en) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
| AU2002233166B2 (en) * | 2001-02-19 | 2006-06-29 | Pharmexa A/S | Synthetic vaccines comprising polyhydroxypolymer carriers |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
-
2003
- 2003-09-12 JP JP2004535024A patent/JP2006504413A/ja active Pending
- 2003-09-12 CA CA002498739A patent/CA2498739A1/en not_active Abandoned
- 2003-09-12 WO PCT/DK2003/000592 patent/WO2004024183A1/en not_active Application Discontinuation
- 2003-09-12 EP EP03794825A patent/EP1539232A1/en not_active Withdrawn
- 2003-09-12 MX MXPA05002699A patent/MXPA05002699A/es not_active Application Discontinuation
- 2003-09-12 AU AU2003263150A patent/AU2003263150A1/en not_active Abandoned
-
2005
- 2005-04-11 NO NO20051779A patent/NO20051779D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004024183B1 (en) | 2004-05-13 |
| JP2006504413A (ja) | 2006-02-09 |
| AU2003263150A1 (en) | 2004-04-30 |
| CA2498739A1 (en) | 2004-03-25 |
| EP1539232A1 (en) | 2005-06-15 |
| WO2004024183A1 (en) | 2004-03-25 |
| NO20051779D0 (no) | 2005-04-11 |
| MXPA05002699A (es) | 2005-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023961L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| WO2003015812A3 (en) | Beta-amyloid-analogue-t-cell epitop vaccine | |
| NO20051779L (no) | Immunisering mot autologt ghrelin | |
| WO2001005820A3 (en) | Method for down-regulating gdf-8 activity | |
| MXPA02007796A (es) | Metodo novedoso para la disminucion de cuerpos amiloides. | |
| US9795666B2 (en) | High-yield transgenic mammalian expression system for generating virus-like particles | |
| DK1543039T3 (da) | Nye immunogene lipopeptider omfattende T-hjælper- og B-celle-epitoper | |
| PT1117421E (pt) | Novos metodos para vacinacao terapeutica | |
| Orellana-Escobedo et al. | An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice | |
| Migliorini et al. | Malaria vaccine: immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity | |
| DK0880360T3 (da) | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop | |
| Yang et al. | Novel T-cell epitopes of ovalbumin in BALB/c mouse: potential for peptide-immunotherapy | |
| NO20040431L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| US20190151440A1 (en) | Mosaic conserved region hiv immunogenic polypeptides | |
| EA200500480A1 (ru) | Иммунизация против аутологичного грелина | |
| MY135691A (en) | Method for down-regulation of gdf-8 activity | |
| Walker et al. | Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes | |
| ECSP003580A (es) | Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8 | |
| Karunakaran et al. | Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development | |
| WO2022109168A3 (en) | Novel var2csa immunogens and methods of use thereof | |
| Hospers et al. | Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen | |
| Wan et al. | HIV/AIDS vaccine development: are we walking out from the dark? | |
| BR102016010178A2 (pt) | Chemical products with potential use as antigenic diagnostic markers and / or recombinant vaccines against toxoplasmose formed through the junction of bet epitopes of ama-1, gra-7 and sag-1 proteins of toxoplasma gondii |